Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 548 citing Kendall: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with.... (0.07 sec) 

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus …

- cardiobarbanza.com [PDF] 
DM Nathan, JB Buse, MB Davidson, E Ferrannini, RR … - Diabetologia, 2009 - Springer
Page 1. CONSENSUS STATEMENT UPDATE Medical management of
hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation
and adjustment of therapy A consensus statement from the American ...
Cited by 1054 - Related articles - BL Direct - All 92 versions

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl …


DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and
suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food
intake. Therapeutic approaches for enhancing incretin action include ...
Cited by 416 - Related articles - All 10 versions

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 …

- annals.org [PDF] 
RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal …, 2005 - Am Coll Physicians
Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control (defined as hemoglobin
A1c level ranging from 7.0% to 10.0%) despite combination metformin and sulfonylurea
therapy. Intervention: Exenatide, 10 g twice daily, or insulin glargine, 1 daily dose titrated ...
Cited by 332 - Related articles - BL Direct - All 7 versions

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and …

- wanfang.gov.tw [DOC] 
RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc
You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Add to CiteULike Add to Connotea Add to ...
Cited by 248 - Related articles - BL Direct - All 8 versions

New sources of pancreatic β-cells


S Bonner-Weir, GC Weir - Nature biotechnology, 2005 - nature.com
Two major initiatives are under way to correct the -cell deficit of diabetes: one would generate
-cells ex vivo that are suitable for transplantation, and the second would stimulate regeneration
of -cells in the pancreas. Studies of ex vivo expansion suggest that -cells have a potential ...
Cited by 175 - Related articles - All 3 versions

Biology of incretins: GLP-1 and GIP

- rh.dk [PDF] 
LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier
This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ...
Cited by 179 - Related articles - All 25 versions

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with …


MA Nauck, S Duran, D Kim, D Johns, J Northrup, A … - Diabetologia, 2007 - Springer
Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority trial was to compare
the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart. Materials
and methods Patients on metformin and a sulfonylurea were randomised to exenatide (n= ...
Cited by 134 - Related articles - BL Direct - All 4 versions

Effects of once-weekly dosing of a long-acting release formulation of exenatide on …

- diabetesjournals.org
D Kim, L MacConell, D Zhuang, PA Kothare, M … - Diabetes Care, 2007 - Am Diabetes Assoc
RESULTS—From baseline to week 15, exenatide LAR reduced mean ± SE A1C by −1.4 ±
0.3% (0.8 mg) and −1.7 ± 0.3% (2.0 mg), compared with +0.4 ± 0.3% with placebo LAR (P < 0.0001
for both). A1C of ≤7% was achieved by 36 and 86% of subjects receiving 0.8 and 2.0 mg ...
Cited by 130 - Related articles - BL Direct - All 5 versions

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled …

- annals.org [PDF] 
B Zinman, BJ Hoogwerf, S Duran Garcia, … - Annals of internal …, 2007 - Am Coll Physicians
Background: Exenatide therapy is effective in combination with metformin or sulfonylureas for
treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are commonly used, but the efficacy
of exenatide with a TZD has not been reported. ... Objective: To compare the effects of ...
Cited by 121 - Related articles - BL Direct - All 5 versions

The physiology of glucagon-like peptide 1

- physiology.org
JJ Holst - Physiological reviews, 2007 - Am Physiological Soc
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal
epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed
in these cells. The current knowledge regarding regulation of proglucagon gene ...
Cited by 119 - Related articles - BL Direct - All 5 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google